| TRADING CENTER |
| Another Deal for Incyte - Analyst Blog - Zacks.com | |
| This Acquisition Is Icy Hot - MotleyFool.com | |
| Tomorrow's Monster Stock? - MotleyFool.com | |
| Some Incyte Into Why These Drugs Rock - MotleyFool.com | |
| 2009 Biotech Cheers and Jeers - MotleyFool.com | |
| PDL BioPharma Announces New Licensing Agreement With Eli Lilly - PR Newswire | |
| Health Care Stocks Can Run Some More ($) - at TheStreet.com | |
| Better Buy: Pfizer or GlaxoSmithKline? - MotleyFool.com | |
| Incyte Licenses Drug to Eli Lilly - at TheStreet.com | |
| Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral... - PR Newswire | |
| 2009: The Year Pharma Learned to Love Itself - MotleyFool.com | |
| 3 Reasons to Sell Dendreon Today - MotleyFool.com | |
| 3 Reasons to Buy Dendreon Today - MotleyFool.com | |
| Daiichi Sankyo Looks For Acquisitions In Continued US Push - Dow Jones | |
| Lilly Finance Chief Given Expanded Responsibilities - Dow Jones |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 64.53 | 0.20 / 0.31% | 14.09 |
| PFE | Pfizer Inc | 18.61 | 0.00 / 0.00% | 15.64 |
| NVS | Novartis AG | 54.22 | 0.42 / 0.78% | 15.23 |
| 2008 Revenue: | $20.4 B | Headquarters: Indianapolis, IN |
| Employees: | 40,450 | CEO: Dr. John C. Lechleiter, Ph.D. |
| Net Income: | $-2,071,900,000.0 | Industry: Pharmaceuticals |
| Market Cap: | $41.6 B | Website: www.lilly.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| LLY | 36.11 | -0.13 / -0.36% | 36.24 | 36.68 | 35.96 | Profile Chart News |